MedTrace Logo

MidregiOnal Proatrial Natriuretic Peptide to Guide SEcondary Stroke Prevention

NCT03961334 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 620

Last updated 2023-08-16

No results posted yet for this study

Summary

The present trial is addressing the question if a biologically distinct subgroup of ischemic stroke patients without known atrial fibrillation at admission, selected by a cut-off level of MRproANP concentration, which represents a underlying increased risk of cardiac thrombogenicity, benefits from direct oral anticoagulation (DOAC) within 7 days of symptom onset versus standard of care (antiplatelet) as preventive treatment.

Conditions

  • Stroke, Ischemic

Interventions

DRUG

Dabigatran

150mg 2x/d

DRUG

Apixaban

5mg 2x/d

DRUG

Edoxaban

60mg 1x/d

DRUG

Aspirin

100mg 1x/d

DRUG

Clopidogrel

75mg 1x/d

Sponsors & Collaborators

  • Swiss National Science Foundation

    collaborator OTHER

  • University of Zurich

    lead OTHER

Principal Investigators

  • Mira Katan, Prof.Dr.med. · University Hospital, Basel, Switzerland

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-12-05
Primary Completion
2025-01-31
Completion
2026-01-31

Countries

  • Greece
  • Norway
  • Spain
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03961334 on ClinicalTrials.gov